Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Developed by Eli Lilly as a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide achieved a mean body weight reduction of -24.2% at its highest dose over 48 weeks surpassing both semaglutide and tirzepatide in their respective pivotal trials
Retatrutide is not approved for alcohol use disorder, and neither is the GLP-1 class as a whole
GLP-1 receptor agonist exenatide uncouples food intake from hedonic and anticipatory regulation in non-human primates: insights from an operant meal schedule paradigm
Ipamorelin keeps this cadence going, coaxing the pituitary to secrete GH in a pattern that mimics the natural one
US$ 26.03
US$ 21.38
US$ 23.11
US$ 25.42
US$ 23.67
